Nabla Connect enables any EHR vendor to deliver world-class ambient AI in days, not months, without the cost, risk, or burden of building in-house. October 16, 2025 — Nabla, one of the most widely ...

JAM has exhibited success rates in de novo design across a range of targets. Credit: PeopleImages/Shutterstock.com. Nabla Bio has entered a new multi-year research ...

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd.

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical, deepening their use of artificial intelligence to ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.

Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI ...

Nabla Bio and Takeda's collaboration focuses on AI-driven protein therapeutics, leveraging the Joint Atomic Model (JAM) platform for de novo antibody design across early-stage programs. Nabla Bio is ...

Nabla Bio cofounders Surge Biswas (left), wearing a white T-shirt. and Frances Anastassacos, in a striped sweatshirt, pose in the company’s laboratory. Nabla Bio cofounders Surge Biswas (left) and ...